Lung - Cancer
This study evaluated the impact of the interval between diagnosis and surgery on mortality in patients with early-stage non-small cell lunger cancer (NSCLC). The results indicated that surgeries performed more than eight weeks after diagnosis...
This week on The Beat, CTSNet Editor-in-Chief Joel Dunning spoke with Timur Kyashif, a cardiac resident at Jena University Hospital in Jena, Germany, about the German Society for Thoracic, Cardiac,...
In this noteworthy interview, CTSNet Editor-in-Chief Joel Dunning speaks with Jeffrey Velotta, Assistant Clinical Professor of Surgery at the University of California, San Francisco School of Medicine in San Francisco,...
This week on The Beat, CTSNet Editor-in-Chief Joel Dunning spoke with Jeffrey Velotta, Assistant Clinical Professor of Surgery at the University of California, San Francisco School of Medicine in San...
This Society of Thoracic Surgeons Expert Consensus Documents provides updated, multidisciplinary guidance on the multimodal management of pleural mesothelioma (PM). The expert panel emphasizes that surgical resection should only be...
Since time to surgery for lung cancer is not well established, researchers aimed to assess whether time to surgery from diagnosis correlates with outcomes like unplanned return to care, mortality,...
The FDA has approved the drug Cytalux for use in lung surgery. The drug, also known as pafolacianine, binds to lung cancer cells to make them glow under infrared light....
Researchers have been awarded a grant to fund cancer vaccine research, including the development of an mRNA vaccine that would target precancerous lung lesions. Eventually, researchers hope to develop an...
This study aimed to establish risk factors for venous thromboembolism (VTE), a significant cause of mortality in lung cancer surgical patients. Unlike in surgical specialties that have adopted postdischarge VTE...
Surgical management for potentially resectable stage IIIA-N2 non-small cell lung cancer (NSCLC) is controversial. In this study, researchers examined outcomes of a well-selected surgical cohort of postinduction IIIA-N2 NSCLC patients...
No statistical significance ,between the two arms, regarding the OVERALL survival in this RCT funded by the supplier and manufacturer of the immunotherapy in question….
...An open-access detailed editorial from the official periodical of the International Association for the Study of Lung Cancer
...A scholarly and sober narrative review on , as the authors state, a ‘ hot topic’ that is already being debated in Multidisciplinary Meetings and Lung Cnacer Boards.
...

